Analysts Set Monopar Therapeutics Inc. (NASDAQ:MNPR) PT at $112.08

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus recommendation of “Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $112.0833.

Several research firms have issued reports on MNPR. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. BTIG Research boosted their price target on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Zacks Research upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th.

Monopar Therapeutics Stock Down 5.5%

Shares of NASDAQ MNPR opened at $108.35 on Tuesday. The stock has a market capitalization of $725.95 million, a price-to-earnings ratio of -57.03 and a beta of 1.46. The stock’s fifty day simple moving average is $85.45 and its 200 day simple moving average is $68.31. Monopar Therapeutics has a 52-week low of $29.18 and a 52-week high of $116.69.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. As a group, analysts anticipate that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Virtu Financial LLC purchased a new stake in shares of Monopar Therapeutics in the fourth quarter valued at $654,000. Siren L.L.C. grew its holdings in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Monopar Therapeutics during the first quarter valued at $3,458,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics during the fourth quarter valued at $188,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.